PIKASSO-01NCT05307705
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 48 versions: 38 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary endpoints: details revised at 2 of 2 entries Show 4 more changesShow less
- Enrollment closed, study ongoing
- Primary completion date changed from estimate of Dec 2026 to Apr 2, 2025
- Eligibility criteria expanded, about 45 words
- Site details revised at 50 of 50 sites
- Minor Site details revised at 4 of 50 sitesv47
- Minor Site details revised at 6 of 50 sitesv46
- Notable Trial status changed: Active, Not Recruiting → Recruiting
- Enrollment increased: 193 → 260 participants
- Site details revised at 50 of 50 sites
- Minor Trial sites expanded: 45 → 50 locationsv44
Show 32 earlier versionsHide 32 earlier versions
- Minor Study sites: 50 to 45v43
- Notable Primary and study completion dates: Dec 2025 to Dec 2026v41
- Minor Site details revised at 20 of 50 sitesv37
- Notable Primary completion date: May 2025 to Dec 2025
- Study sites: 55 to 50
- Minor Study completion date: May 2025 to Dec 2025
- Study sites revised (55)
- Minor Collaborators shortened, about 3 wordsv32
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 400 to confirmed 193
- Site details revised at 55 of 55 sites
- Minor Site details revised at 1 of 55 sitesv28
- Minor Study sites: 48 to 55v27
- Minor Study sites: 44 to 48v26
- Minor Study sites: 41 to 44v25
- Minor Study sites: 39 to 41v24
- Minor Study sites: 35 to 39v23
- Minor Study sites: 33 to 35v22
- Minor Study sites: 31 to 33v21
- Notable Primary endpoints revised (2)
- Eligibility criteria expanded, about 18 words
- Secondary endpoints: details revised at 1 of 10 entries
- Minor Study sites: 24 to 31v19
- Minor Study sites: 23 to 24v18
- Minor Study sites: 21 to 23v17
- Minor Study sites: 20 to 21v16
- Minor Study sites: 14 to 20v15
- Minor Enrollment target: 300 to 400
- Eligibility criteria expanded, about 34 words
- Study arms: 6 to 7
- Minor Study sites: 12 to 14v13
- Minor Study sites: 11 to 12v12
- Minor Study sites: 10 to 11v10
- Minor Study sites: 8 to 10v9
- Minor Study sites: 7 to 8v8
- Minor Enrollment target: 260 to 300
- Study sites: 5 to 7
- Eligibility criteria expanded, about 9 words
- Minor Study sites: 4 to 5v5
- Minor Site contacts updated at 4 of 4 sitesv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 4
- Start date changed from estimate of Apr 2022 to May 11, 2022
- Study Status, Referencesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
LOXO-783 administered orally
LOXO-783 administered orally in combination with fulvestrant intramuscularly, imlunestrant orally, or an aromatase inhibitor orally
LOXO-783 orally in combination with abemaciclib and either physician's choice aromatase inhibitor orally, fulvestrant intramuscularly, or imlunestrant orally
LOXO-783 orally in combination with fulvestrant intramuscularly
LOXO-783 orally in combination with paclitaxel intravenously
LOXO-783 orally
Multiple randomized dose levels of LOXO-783 orally with fulvestrant intramuscularly
Drugs: LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, Paclitaxel
Sites
50 sites in 12 countries
United States 17, Spain 8, France 5, Japan 4, Australia 3, China 3, Belgium 2, Canada 2, South Korea 2, United Kingdom 2, Germany 1, Singapore 1